Followers | 355 |
Posts | 9910 |
Boards Moderated | 2 |
Alias Born | 06/23/2007 |
Tuesday, September 08, 2015 1:54:46 PM
It began with shares trading just around the rights offering was priced at ($2/share). There were a LOT of naysayers who said management wouldn't get the rights offering completed...they'd fail, etc.
Well management got the offering done and stock doubled over the next 6-8 weeks.
I fully expect the same thing to happen now. Keep in mind it will only take a handful of large investors to complete the offering- these are investors that know the coming acquisition buzz following the rights offering will be good for a big move in the stock. That's how it played out in March and how it will play out now in my opinion.
I'll be updating my subscribers at MicrocapResearch.com with 2 updated articles on HOTR in the next week. Share price has never been better and fundamentals, particularly + EBITDA has never been better.
Recent SONN News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 12:36:17 PM
- Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors • GlobeNewswire Inc. • 09/18/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 09:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:08:40 PM
- Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series • GlobeNewswire Inc. • 09/04/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 12:30:39 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/19/2024 09:28:17 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/19/2024 09:27:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 12:50:25 PM
- Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 08/19/2024 12:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 12:45:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:41:20 PM
- Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/14/2024 12:35:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/09/2024 09:28:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 12:36:15 PM
- Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study • GlobeNewswire Inc. • 07/24/2024 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/15/2024 09:05:56 PM
- Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds • GlobeNewswire Inc. • 06/20/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:15:34 PM
- Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain • GlobeNewswire Inc. • 06/13/2024 12:00:00 PM
- Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting • GlobeNewswire Inc. • 05/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 11:35:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 01:25:20 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM